Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
Positive Phase 1 MYCHELANGELO trial showed 50% disease control rate in HCC patients Reduced net loss to $16.4M in Q3 2024 from $22.2M in Q3 2023 R&D expenses decreased by $3.7M compared to Q3 2023 G&A expenses reduced by $1.0M compared to Q3 2023 Ongoing collaboration with Novo Nordisk for obesity program Negative $30.4M cash runway only extends into Q2 2025 Deprioritization of OTX-2101 and CXCL1-8 programs Phase 2 development of OTX-2002 dependent on finding strategic partners
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Daight
Jaguar8
OP
:
when you try to help but others accuse you of being a short. bet that person is in the deep and still holding, defense mechanism kicked in, mind cleared out every piece of bad news, as if it did not happen at all, similar to myths of ostriches burying their head in the ground, see no baddie=baddie don't exist.
Jaguar8 OP Krystian 1983 : ??? Who sold 5K? I didn’t
Daight Jaguar8 OP : when you try to help but others accuse you of being a short.
bet that person is in the deep and still holding, defense mechanism kicked in, mind cleared out every piece of bad news, as if it did not happen at all, similar to myths of ostriches burying their head in the ground, see no baddie=baddie don't exist.
Jaguar8 OP Daight : So maybe give that remark to somebody else because I ain’t a short
Krystian 1983 : As I’m remembering this is always bounce back to 1,3-1,6 always